UpFront Diagnostics

Executive Summary

UpFront Diagnostics, a UK-based medtech company founded in 2018, has developed LVOne, the world’s first rapid lateral flow blood test for detecting Large Vessel Occlusion (LVO) strokes at the point of care. Designed for use outside hospital settings, LVOne aims to dramatically reduce time-to-treatment by enabling paramedics and emergency clinicians to identify LVO strokes within minutes using a simple blood test. This innovation addresses a critical gap in stroke care, where every minute saved improves patient outcomes and reduces disability. The company is targeting pre-hospital and emergency department deployment, positioning LVOne as a transformative tool in stroke diagnostics. The global stroke diagnostics market is substantial, with LVO strokes accounting for a significant portion of severe cases that require timely intervention. Current diagnostic methods rely on advanced imaging (CT/MRI) typically available only in hospitals, causing delays. UpFront’s point-of-care test could revolutionize triage by allowing rapid identification of LVO patients, accelerating transfer to thrombectomy-capable centers. With a strong IP portfolio and early positive data, the company is poised to capture significant market share. However, regulatory and commercial execution risks remain. Overall, UpFront Diagnostics presents a compelling opportunity in a high-need area with clear unmet clinical demand.

Upcoming Catalysts (preview)

• Q3 2026CE marking approval for LVOne in EU/UK70% success
• Q4 2026Publication of pivotal clinical study results in peer-reviewed journal80% success
• H1 2027Strategic partnership with a major stroke network or hospital group50% success